Financials data is unavailable for this security.
View more
Year on year BrightGene Bio-Medical Technology Co Ltd had net income fall -15.51% from 239.62m to 202.47m despite a 15.94% increase in revenues from 1.02bn to 1.18bn. An increase in the cost of goods sold as a percentage of sales from 38.43% to 46.03% was a component in the falling net income despite rising revenues.
| Gross margin | 54.97% |
|---|---|
| Net profit margin | 11.55% |
| Operating margin | 12.94% |
| Return on assets | 2.91% |
|---|---|
| Return on equity | 7.95% |
| Return on investment | 3.57% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at BrightGene Bio-Medical Technology Co Ltd fell by 180.69m. However, the company earned 194.77m from its operations for a Cash Flow Margin of 16.51%. In addition the company generated 61.61m cash from financing while 439.85m was spent on investing.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 5.57 |
|---|---|
| Tangible book value per share | 5.32 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.56 |
|---|---|
| Quick ratio | 1.18 |
| Total debt/total equity | 0.9345 |
|---|---|
| Total debt/total capital | 0.4841 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -15.79% and -17.24%, respectively. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.29% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 43.09% |
| EPS growth(5 years) | 17.98 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -18.46 |
More ▼
